MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Начало・Списък с акции・Merck & Co Inc.

Merck & Co Inc.

Затворен

СекторЗдравеопазване

86.47 -0.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

86.26

Максимум

88.77

Ключови измерители
By Trading Economics
Приходи	583M 3.7B
Продажби	-1B 16B
P/E Средно за сектора	13.318 63.778
EPS	1.72
Дивидентна доходност	3.61
Марж на печалбата	23.963
Служители	73,000
EBITDA	1.3B 6.9B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+29.19% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	3.61% 2.39%
Следващи печалби	24.04.2025 г.
Следваща дата на дивидент	7.04.2025 г.
Следваща дата на екс-дивидент	16.06.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-26B 227B
Предишно отваряне	86.62
Предишно затваряне	86.47

Настроения в новините

By Acuity

39%

61%

145 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

N/A / 93.07 Подкрепа & съпротива

Merck & Co Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2025 г., 12:33 ч. UTC

Печалби

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4.02.2025 г., 11:57 ч. UTC

Печалби

Merck 4Q Sales Increase Results in Swing to Profit

24.03.2025 г., 05:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5.03.2025 г., 19:42 ч. UTC

Топ новини

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5.03.2025 г., 10:30 ч. UTC

Топ новини

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5.02.2025 г., 12:00 ч. UTC

Топ новини

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4.02.2025 г., 14:48 ч. UTC

Печалби

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4.02.2025 г., 11:51 ч. UTC

Печалби

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4.02.2025 г., 11:50 ч. UTC

Печалби

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4.02.2025 г., 11:31 ч. UTC

Печалби

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4.02.2025 г., 11:31 ч. UTC

Печалби

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4.02.2025 г., 11:31 ч. UTC

Печалби

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

4.02.2025 г., 11:31 ч. UTC

Печалби

Merck 4Q Januvia/Janumet Sales $487M >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck 4Q Keytruda Sales Up 19% >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck 4Q Keytruda Sales $7.84B >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck 4Q Pharmaceutical Sales Up 7% >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck 4Q Pharmaceutical Sales $14.04B >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck Sees FY Rev $64.1B-$65.6B >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck 4Q Adj EPS $1.72 >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck 4Q Net $3.74B >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

4.02.2025 г., 11:30 ч. UTC

Печалби

Merck 4Q Winrevair Sales $200M >MRK

Сравнение с други в отрасъла

Ценова промяна

Merck & Co Inc. Прогноза

Ценова цел

By TipRanks

29.19% нагоре

12-месечна прогноза

Среден 111.88 USD 29.19%

Висок 138 USD

Нисък 95 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Merck & Co Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

17 ratings

Купи

Задържане

Продай

Според 17 анализатори, дали борсови рейтинги на Merck & Co Inc. през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 93.07Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

145 / 386 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.